No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults.
about
Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replicationInfectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventionsIncidence of herpes simplex virus type 2 infections in Africa: a systematic reviewDaily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with menIntravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infectionTenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 InfectionPotential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in femalesOral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial.Genital Herpes Simplex Virus Type 2 Shedding Among Adults With and Without HIV Infection in Uganda.Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract SheddingMicrobicides: still a long road to successAntiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1.Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 InfectionTenofovir: quo vadis anno 2012 (where is it going in the year 2012)?Herpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease.Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study.Herpes simplex virus genital infections: current concepts.
P2860
Q24634299-C744241B-7837-44F4-98DD-9805208B2F81Q26823594-D569079B-1442-4DB4-9292-245B49A8257AQ27690876-C4B88C08-A26D-4B77-AEBF-48BE5EF17862Q28540969-9C28229A-7FFA-45B8-8EF0-E51298C92CF2Q36018953-C3AF985D-809F-4AA7-BE94-6FC48EB800F6Q36034465-8C6AF12A-A3FE-4B14-973B-A77B7F26C3BBQ36173112-08CCB9A4-A410-4C09-A9CA-45195B670181Q36306926-BC956926-E771-4C60-AA82-C541D80CCC6FQ36440266-48B889D3-918B-4845-B629-539A4C860CCDQ36630996-A2F89087-ECC6-447E-9DA2-83567CCDBBA1Q37130757-EF0D4EF0-0F5C-49D0-8BEB-1DB81CBC4250Q37694939-C61DC5EE-419F-4F88-A00B-940C125F45DEQ37705969-22C89343-1275-465E-8E3E-8118ACA4E39BQ38009758-7EDCA8E4-00A3-4B07-9D80-F968AB5B88B3Q38248209-9D3EB8DB-1E3B-4F26-B79D-36FF1C617EEFQ40223007-9C1010AF-5E1D-4F6F-8248-A38D8DC0C19AQ45363913-5367C90A-177F-4F0E-A91B-2484636317FB
P2860
No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
No impact of oral tenofovir di ...... edding in HIV-infected adults.
@en
No impact of oral tenofovir di ...... edding in HIV-infected adults.
@nl
type
label
No impact of oral tenofovir di ...... edding in HIV-infected adults.
@en
No impact of oral tenofovir di ...... edding in HIV-infected adults.
@nl
prefLabel
No impact of oral tenofovir di ...... edding in HIV-infected adults.
@en
No impact of oral tenofovir di ...... edding in HIV-infected adults.
@nl
P2093
P1433
P1476
No impact of oral tenofovir di ...... edding in HIV-infected adults.
@en
P2093
Darrell Hs Tan
Janet M Raboud
Sharon L Walmsley
P304
P356
10.1097/QAD.0B013E328341DDF7
P407
P50
P577
2011-01-01T00:00:00Z